Personalized Cell Therapy Market By Therapy Type (Autologous Cell Therapy, Allogeneic Cell Therapy), By Application (Cancer Treatment, Genetic Disorders, Autoimmune Diseases, Regenerative Medicine), By End-User (Hospitals, Research Institutions, Cell Therapy Providers), By Technology (CRISPR-based Therapies, Stem Cell Therapies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Personalized Cell Therapy Market was valued at USD 9.9 billion in 2024-e and will surpass USD 15.2 billion by 2030; growing at a CAGR of 7.5% during 2025 - 2030.

The personalized cell therapy market is rapidly advancing as new technologies enable more targeted and effective treatments for various medical conditions. This innovative approach to healthcare allows for the use of a patient's own cells or donor cells to treat diseases, offering the potential for more tailored, individualized treatments. Personalized cell therapies are particularly promising in fields like cancer treatment, genetic disorders, autoimmune diseases, and regenerative medicine, where traditional treatment methods may not offer sufficient efficacy or specificity. The use of cutting-edge technologies such as CRISPR and stem cell therapies further drives innovation in this sector, opening new possibilities for precision medicine.

The market is experiencing strong growth due to increased investment in research and development, as well as the growing awareness among healthcare providers and patients about the potential benefits of personalized therapies. Moreover, the development of advanced technologies and improved regulatory frameworks are facilitating the approval and widespread use of these treatments. As the healthcare sector moves toward more personalized and patient-centered care, the personalized cell therapy market is expected to expand significantly, offering new hope for patients with previously untreatable conditions.

Autologous Cell Therapy Therapy Type is Largest Owing to High Efficacy and Lower Risk of Rejection

The autologous cell therapy type is the largest in the personalized cell therapy market owing to its high efficacy and lower risk of immune rejection. Autologous cell therapy involves using a patient's own cells for treatment, ensuring compatibility and minimizing the chances of immune response or graft rejection. This approach is particularly valuable in the treatment of cancer, autoimmune diseases, and genetic disorders, where tailored therapies can address the specific needs of the individual. The use of autologous cells also simplifies the regulatory approval process, as these therapies do not involve complex ethical concerns related to donor cells.

The growing adoption of autologous cell therapies is also fueled by advancements in cell culture and genetic modification techniques, which allow for the enhancement and modification of cells for improved therapeutic outcomes. As these treatments continue to demonstrate success in clinical trials, the autologous cell therapy segment is expected to remain the dominant force in the personalized cell therapy market.

Cancer Treatment Application is Largest Owing to Rising Incidence of Cancer and Advances in Immunotherapies

The cancer treatment application is the largest in the personalized cell therapy market owing to the rising incidence of cancer and significant advances in immunotherapies. Personalized cell therapies, such as CAR-T (chimeric antigen receptor T-cell) therapy, have shown promise in treating various types of cancer, including leukemia, lymphoma, and solid tumors. These therapies involve genetically modifying a patient's T-cells to recognize and attack cancer cells, offering a more targeted and effective treatment compared to traditional chemotherapy or radiation. The success of CAR-T therapies has accelerated the development of other personalized cancer treatments, further propelling this application.

The increasing prevalence of cancer worldwide, coupled with the demand for more effective treatments, is driving the growth of this segment. Personalized therapies are viewed as a transformative approach to cancer care, offering the potential for long-term remission and improved survival rates. As more personalized therapies for cancer enter the market, the cancer treatment application is expected to continue to lead the way in the personalized cell therapy market.

Research Institutions End-User Segment is Fastest Growing Owing to Advancements in Scientific Discoveries

The research institutions end-user segment is the fastest growing in the personalized cell therapy market owing to advancements in scientific discoveries and innovations in cell-based therapies. Research institutions play a crucial role in the development and refinement of personalized cell therapies by conducting clinical trials, exploring new therapeutic approaches, and advancing our understanding of cell biology. These institutions are often at the forefront of discovering new methods for genetic modification, cell rejuvenation, and immune system modulation, which are vital to the growth of the personalized cell therapy sector.

As the scientific community continues to make breakthroughs in genomics and cell engineering, research institutions will remain essential to driving the future of personalized therapies. Their work in developing novel treatments for cancer, genetic disorders, and autoimmune diseases is expected to accelerate the growth of the personalized cell therapy market in the coming years.

CRISPR-based Therapies Technology is Fastest Growing Owing to Breakthroughs in Gene Editing

The CRISPR-based therapies technology is the fastest growing in the personalized cell therapy market owing to breakthroughs in gene editing. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology allows for precise alterations to DNA, enabling the correction of genetic defects and the modification of cells for therapeutic purposes. This technology is revolutionizing the field of personalized medicine, offering the potential to treat genetic disorders and cancers at the molecular level. The ability to edit genes with unprecedented accuracy and efficiency makes CRISPR-based therapies an exciting area of growth within the personalized cell therapy sector.

The development of CRISPR-based therapies has opened new doors for the treatment of conditions that were previously considered untreatable, such as certain inherited genetic disorders. With its ability to target specific genes, CRISPR offers a more tailored and effective approach to treatment, leading to its rapid adoption in the personalized cell therapy market. As further research and clinical trials demonstrate the success of CRISPR-based therapies, this technology is expected to become a dominant force in the sector.

North America Region is Largest Owing to Strong Healthcare Infrastructure and Investment in R&D

North America is the largest region in the personalized cell therapy market owing to its strong healthcare infrastructure, high levels of investment in research and development, and the presence of leading biotechnology and pharmaceutical companies. The United States, in particular, has been at the forefront of developing and commercializing personalized cell therapies, with significant support from government agencies, regulatory bodies, and private sector investments. North America is home to many of the pioneering research institutions and clinical trial centers driving the advancement of personalized therapies, particularly in cancer treatment and genetic disorders.

The region’s robust healthcare system, along with a high rate of adoption of cutting-edge medical technologies, positions North America as the dominant player in the personalized cell therapy market. The growing demand for innovative treatments, coupled with the supportive regulatory environment, is expected to ensure that North America remains a key region for the growth of personalized cell therapies.

Leading Companies and Competitive Landscape

Leading companies in the personalized cell therapy market include Novartis, Gilead Sciences, Bristol-Myers Squibb, and Kite Pharma, which are known for their expertise in gene therapies, CAR-T treatments, and stem cell-based therapies. These companies are at the forefront of developing and commercializing personalized cell therapies, with a strong focus on innovation, clinical trials, and regulatory approvals. In particular, CAR-T therapies from companies like Gilead’s Kite Pharma and Bristol-Myers Squibb have been significant contributors to the success of personalized cell therapies in cancer treatment.

The competitive landscape is marked by a strong focus on research and development, as well as strategic partnerships and acquisitions aimed at expanding product portfolios. Companies are investing heavily in advanced gene editing technologies such as CRISPR to stay ahead of the competition and offer more effective treatments. As the personalized cell therapy market continues to grow, it is expected that competition will intensify, with more players entering the market and contributing to its expansion through innovative solutions and therapies.

Recent Developments:

• In December 2024, Novartis AG received regulatory approval for its autologous CAR T-cell therapy, offering a new treatment for specific types of cancer.
• In November 2024, Gilead Sciences announced a new partnership with academic research institutions to develop next-generation personalized cell therapies for genetic disorders.
• In October 2024, Bristol Myers Squibb expanded its cell therapy pipeline with the acquisition of a promising stem cell therapy company for autoimmune diseases.
• In September 2024, Kite Pharma launched an advanced cell therapy product that utilizes CRISPR-based gene editing to treat certain cancers.
• In August 2024, Mesoblast Limited entered into a collaboration with a global hospital network to accelerate clinical trials for its regenerative medicine therapies.

List of Leading Companies:

• Novartis AG
• Gilead Sciences, Inc.
• Bristol Myers Squibb
• Kite Pharma (a Gilead Company)
• Thermo Fisher Scientific
• Bluebird Bio, Inc.
• Juno Therapeutics (a Bristol Myers Squibb Company)
• Cellectis S.A.
• Cell Medica
• Mesoblast Limited
• Esperite N.V.
• Adaptimmune Therapeutics PLC
• Sangamo Therapeutics
• 3D Medicines Co., Ltd.
• TCR2 Therapeutics

Report Scope: